La Jolla Proceeds With Additional Riquent Dosing Study
This article was originally published in The Pink Sheet Daily
Executive Summary
High doses of lupus agent appear to be "well-tolerated" in healthy volunteers, firm says. Dose-response data are being collected in response to FDA's "approvable" letter. La Jolla plans to add the information to ongoing pivotal trial.
You may also be interested in...
Prestara Changes Course: Development To Focus on Lupus Signs And Symptoms
Genelabs will no longer pursue a Prestara indication for prevention of loss of bone mineral density in women with lupus.
Genelabs To Meet With FDA Following Positive Open-Label Prestara Study
The study was an extension of a previous Phase III study that failed to meet its primary endpoint of increased bone mineral density at the lumbar spine.
Genelabs To Meet With FDA Following Positive Open-Label Prestara Study
The study was an extension of a previous Phase III study that failed to meet its primary endpoint of increased bone mineral density at the lumbar spine.